Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated July 1, 2020, reports on a significant corporate transaction entered into on June 30, 2020. The Company, a biopharmaceutical firm focused on developing nomacopan and other product candidates, announced a securities purchase agreement with Aspire Capital Fund, LLC.
Key Financial Metrics and Transaction Details
The filing details a committed financing facility rather than historical operating results. Key financial terms include:
- Commitment Amount: Aspire Capital is committed to purchase up to $30.0 million of the Company's American Depositary Shares (ADSs).
- Term: The agreement covers a 30-month period.
- Commitment Shares: The Company issued 40,760,900 Ordinary Shares to Aspire Capital as consideration for entering the agreement.
- Pricing Mechanism: The purchase price is the lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding ten business days. A Volume-Weighted Average Price (VWAP) option allows purchases at 97% of the VWAP.
- Use of Proceeds: Expected to be used for working capital and general corporate purposes.
- Financial Covenants: The filing explicitly states there are no financial or business covenants, restrictions on future funding, or limitations on the use of proceeds.
Note: This filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes
The primary material change is the establishment of a new equity financing facility. This provides the Company with a mechanism to raise capital up to $30.0 million over the next 30 months at its sole discretion, subject to a minimum price floor of $0.25 per ADS. Unlike traditional equity offerings, the Company controls the timing and amount of sales, and Aspire Capital has no right to require sales.
Outlook, Risks, and Management Commentary
Management highlights the flexibility of the agreement, noting the Company can terminate it at any time without cost. However, the filing includes extensive forward-looking statements and risk factors, including:
- Capital Needs: Risks regarding the need for additional capital to fund operations and the ability to continue as a going concern.
- Regulatory and Clinical Risks: Uncertainties in obtaining regulatory approvals for nomacopan, clinical trial results, and patient enrollment difficulties.
- Market and Operational Risks: Risks associated with the coronavirus outbreak, an ongoing SEC investigation, intellectual property enforcement, and reliance on third-party manufacturers.
- Short-Selling Restrictions: Aspire Capital is prohibited from engaging in short-selling or hedging of the Company's securities during the term of the agreement.
Investor Verification Checklist
- Verify the current market price of Akari Therapeutics ADSs relative to the $0.25 minimum price floor required for sales under the agreement.
- Review the Company's most recent Form 20-F for detailed cash position and burn rate to assess the immediate necessity of utilizing this facility.
- Confirm the status of the SEC investigation mentioned in the risk factors.
- Monitor the dilution impact of the 40,760,900 Commitment Shares already issued and potential future issuances up to the $30.0 million cap.
- Check for updates on the clinical trial progress of nomacopan, the Company's primary product candidate.